Neumonía en un paciente con trasplante renal tratado con alirocumab y everolimus

Lucía Ordóñez-Fernández; Adrián Rodríguez-Ferreras; Carmen Carriles; Alba Martínez-Torrón; Eva Lázaro-López; María Carmen Rosado-María

doi:10.7399/fh.11138

Neumonía en un paciente con trasplante renal tratado con alirocumab y everolimus

Lucía Ordóñez-Fernández, Adrián Rodríguez-Ferreras, Carmen Carriles, Alba Martínez-Torrón, Eva Lázaro-López, María Carmen Rosado-María

Resumen

Palabras clave

Texto completo:

PDF (English) PDF

Referencias

Zodda D, Giammona R, Schifilliti S. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy. 2018;6:1. DOI:10.3390/pharmacy6010010

Ryan A, Nevitt SJ, Byrne CD, Cook P. PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. Cochrane Database Syst Rev. 2018;1:CD012917. DOI: 10.1002/14651858.CD012917

Rosenson RS, Durrington P MD. Familial hypercholesterolemia in adults: Treatment. UpToDate [updated 5/2017] [accessed 8/7/2018]. Available at: https://www.uptodate.com/contents/familial-hypercholesterolemia-inadults-treatment? search=hipercolesterolemia%20familiar&source=search_result&select edTitle=1~87&usage_type=default&display_rank=1

Agencia Española de Medicamentos y Productos Sanitarios. Ficha Técnica de evolocumab. Centro de información de medicamentos (CIMA) [web page] Madrid. Agencia Española de Medicamentos y Productos Sanitarios. [accessed 8/7/2018]. Available at: https://cima.aemps.es/cima/pdfs/ft/1151016003/FT_1151016003.pdf

Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de alirocumab. Centro de información de medicamentos (CIMA) [web page] Madrid. Agencia Española de Medicamentos y Productos Sanitarios. [accessed 8/7/2018]. Available at: https://cima.aemps.es/cima/dochtml/ft/1151031008/FT_1151031008 .html

Agencia Española de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terapéutico IPT-Alirocumab/V1/22042016. [web page] Madrid [accessed 25/4/2018]. Available at: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublic os/docs/IPT-alirocumab-Praluent-hipercolesterolemia.pdf

Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;12:CD007746. DOI: 10.1002/14651858.CD007746

Brennan DC, Lentine KL. Lipide abnormalities after renal transplantation. UpTo-Date [internet]. Netherlands. Wolters Kluwer [updated 1/6/2018] [accessed 8/7/2018]. Available at: https://www.uptodate.com/contents/lipid-abnormalities-after-renal- transplantation?search=.%20Lipide%20abnormalities%20after%20renal%20transplan tation.&source=search_result&selectedTitle=1~150&usage_type=defa ult&display_rank=1

Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R, et al.; National Kidney Foundation. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4(Suppl 7):13-53.

Snell GI, Valentine VG, Vitulo P, Glanville AR, McGiffin DC, Loyd JE, et al. Everolimus Versus Azathioprine in Maintenance Lung Transplant Recipients: An International, Randomized, Double-Blind Clinical Trial. Am J Transplant. 2006;6(1):169-77

DOI: http://dx.doi.org/10.7399%2Ffh.11138